A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis.

Trial Profile

A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Natalizumab (Primary) ; Keyhole limpet haemocyanin; Tetanus toxoid
  • Indications Multiple sclerosis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Biogen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 28 Oct 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top